# US 2012/0083511 A1 · Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083511 A1
- Document ID: US20120083511A1
- Status: Published application
- Kind: A1
- Application number: 13/248,055
- Filed: 2011-09-29
- Published: 2012-04-05
- Earliest claimed: 2010-10-05
- Assignees: Eli Lilly and Company
- Inventors: Benjamin Alan Diseroad
- Web page: https://patentgrep.com/patent/US20120083511A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol useful in the treatment of cancer.

## Claims

### Claim 1

A compound which is crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol.

### Claim 2 (depends on 1)

The compound according to claim 1 which is isolated.

### Claim 3 (depends on 1)

The compound according to claim 1 which is crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol monohydrate.

### Claim 4 (depends on 3)

The compound according to claim 3 which is isolated.

### Claim 5 (depends on 1)

The compound according to claim 1 characterized by the X-ray powder diffraction pattern (Cu radiation, λ=1.54059 Å) comprising a peak at 14.65, and one or more peaks at 3.54, 12.51, or 19.16 (2θ+/−0.1°).

### Claim 6 (depends on 2)

The compound according to claim 2 characterized by the X-ray powder diffraction pattern (Cu radiation, λ=1.54059 Å) comprising a peak at 14.65, and one or more peaks at 3.54, 12.51, or 19.16 (2θ+/−0.1°).

### Claim 7 (depends on 3)

The compound according to claim 3 characterized by the X-ray powder diffraction pattern (Cu radiation, λ=1.54059 Å) comprising a peak at 14.65, and one or more peaks at 3.54, 12.51, or 19.16 (2θ+/−0.1°).

### Claim 8 (depends on 4)

The compound according to claim 4 characterized by the X-ray powder diffraction pattern (Cu radiation, λ=1.54059 Å) comprising a peak at 14.65, and one or more peaks at 3.54, 12.51, or 19.16 (2θ+/−0.1°).

### Claim 9

A pharmaceutical composition comprising crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol in combination with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 10

A pharmaceutical composition comprising crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol monohydrate in combination with a pharmaceutically acceptable carrier, diluent or excipient.
